CAP对儿童非酒精性脂肪性肝病的诊断价值研究<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2021.03.006

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1251 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨CAP对儿童非酒精性脂肪性肝病(NAFLD)的临床诊断价值。【方法】选择2016年8月至2020年9月本院肝病中心收治的91例NAFLD患儿,均经肝脏组织活检,同时进行受控衰减参数(CAP)检查。另选取30例其他肝病患儿为对照组,经肝活检证实无肝脂肪变性,同时也进行CAP检测。运用儿童NAFLD组织学评分系统对肝脂肪变性进行分级,并进行相关性分析。【结果】观察组患儿BMI、门冬氨酸转移酶(AST)、丙氨酸转氨酶(ALT)、谷氨酰转移酶(GGT)、CAP、总胆固醇(TC)、三酰甘油(TG)均大于对照组,差异有统计学意义( P <0.05)。CAP区分有无肝脂肪变性的 AUC 为0.955,最佳截断值为222.5 dB/m, 95%CI 为0.91~1.00,为94.5%、特异性为86.7%,按最佳截断值评估观察组肝脂肪变性准确率为94.51%(86/91)。BMI与CAP具有显著相关性( r=0.241,P =0.021<0.05)。【结论】CAP对儿童NAFLD的诊断有较高的临床价值,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：非酒精性脂肪性肝病/诊断, 弹性成像技术, 超声检查, 儿童

Abstract：【Objective】To evaluate the clinical diagnostic value of CAP in children with NAFLD fatty liver. 【Methods】From August 2016 to September 2020, 91 children with NAFLD were selected from the liver disease center of our hospital. All patients underwent liver biopsy and controlled attenuation parameter (CAP) examination. Another 30 children with other liver diseases were selected as the control group. No hepatic steatosis was confirmed by liver biopsy, and cap was also detected. NAFLD histological scoring system was used to grade hepatic steatosis, and correlation analysis was performed. 【Results】The BMI, AST, ALT, GGT, CAP, TC and TG of the observation group were higher than those of the control group ( P <0.05). The AUC of cap was 0.955, the best cut-off value was 222.5 dB/m, the 95%CI was 0.91-1.00, which was 94.5%, and the specificity was 86.7%. According to the best cut-off value, the accuracy of liver steatosis in the observation group was 94.51% (86/91). BMI was significantly correlated with CAP ( r=0.241, P =0.021<0.05).【Conclusion】 Cap has high clinical value in the diagnosis of NAFLD in children, which is worthy of clinical application.

Key words： Non-alcoholic Fatty Liver Disease/DI Elasticity Imaging Techniques Ultrasonography Child

收稿日期: 2021-01-12

中图分类号:

R575.5

基金资助:*湖南省自然科学基金(2018JJ2209)

通讯作者: **,E-mail:2273858951@qq.com

引用本文:

刘敏, 郑曦, 仇君, 何舒丽, 陈卫坚, 周峥珍, 欧阳文献, 康桢, 李双杰. CAP对儿童非酒精性脂肪性肝病的诊断价值研究^*[J]. 医学临床研究, 2021, 38(3): 343-345.
LIU Min, ZHENG Xi, QIU Jun, et al. Diagnostic Value of CAP in Children with Nonalcoholic Fatty Liver Disease. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 343-345.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.03.006 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I3/343

[1] Paul WH, Susann WB.Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives[J]. Current Obesity Reports, 2019, 8(4):472-479.
[2] Anderson EL, Howe LD, Jones HE, et al . The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(10): e0140908.
[3] Pu K, Wang YP, Bai SY, et al . Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2019, 19:51.
[4] Vos MB, Abrams SH, Barlow SE, et al . NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children:recommendations from the expert committee on NAFLD (ECON) and the north american society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN)[J]. J Pediatr Gastroenterol Nutr, 2017, 64(2):319-334.
[5] Alkhouri N, Vito RD., Alisi A, et al . Development and Validation of a New Histological Score for Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)[J]. J Hepatol, 2012, 57(6):1312-1318.
[6] 南月敏. 2017美国非酒精性脂肪性肝病诊断与管理指南解读[J].中华肝脏病杂志,2017, 25(9):687-694.
[7] Ivana M, Lidija O, Neven F, et al . Transient elastography (FibroScan^®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-Where do we stand?[J]. World J Gastroenterol, 2016,22(32): 7236-7251.
[8] 宋旭光,何玉冰.瞬时弹性成像在NAFLD患者肝纤维化和脂肪变性检测中的临床应用[J].肝脏, 2020, 25(5):536-538.
[9] Park CC, Nguyen P, Hernandez C, et al . Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017,152(3):598-607.
[10] Desai NK, Harney S, Raza R, et al . Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients[J]. Journal of Pediatrics, 2016, 173:160-164.
[11] Siddiqui MS.Vibration-controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease[J]. Clinical Gastroenterology & Hepatology, 2019,17(1): 156-163.
[12] Pu K, Wang Y, Bai S, et al . Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. BMC Gastroenterology, 2019, 19(1):51.
[13] Jung KS, Kim BK, Kim SU, et al .Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease[J]. PLoS One, 2014,9(6):e98689.